Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Wave Life Sciences Ltd.

Biotech Giants: SG&A Expense Trends Over a Decade

__timestampACADIA Pharmaceuticals Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 2014327480002999000
Thursday, January 1, 20159080400010393000
Friday, January 1, 201618645600015994000
Sunday, January 1, 201725506200026975000
Monday, January 1, 201826575800039509000
Tuesday, January 1, 201932563800048869000
Wednesday, January 1, 202038866100042510000
Friday, January 1, 202139602800046105000
Saturday, January 1, 202236909000050513000
Sunday, January 1, 202340246600051292000
Loading chart...

Unlocking the unknown

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Wave Life Sciences Ltd. over the past decade. From 2014 to 2023, ACADIA Pharmaceuticals saw a staggering 1,130% increase in SG&A expenses, peaking in 2023. In contrast, Wave Life Sciences experienced a more modest 1,610% rise, reflecting its strategic growth phase. Notably, ACADIA's expenses consistently outpaced Wave's, highlighting its aggressive market strategies. By 2023, ACADIA's SG&A expenses were nearly eight times higher than Wave's, underscoring its expansive operational scale. This financial trajectory offers insights into each company's strategic priorities and market positioning, providing a window into the dynamic landscape of the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025